No replies to this topic

[GerryL]

Abstract

A revolution in medical science was marked with the advent of imatinib, a site specific drug

for the management of patients with chronic myeloid leukemia (CML). Imatinib mesylate

(also known as Glivec, Gleevec, STI-571, CGP57148), an orally administered 2-

phenylaminopyrimidine derivative approved by FDA in 2001 for treatment of CML is highly

effective in treating the early stages of chronic myeloid leukemia, but remission induced in

advanced phase were observed to be relatively short lived. The primary cause of resistance in

CML patients is the mutations in the BCR/ABL kinase domain. This review discusses the

different mechanisms leading to Imatinib resistance and various treatment options to over

ride imatinib resistance. http://onlinelibrary...011.01689.x/pdf